VivoSeq
Infectious Disease

COVID-19 Infection

5

Pipeline Programs

5

Active Trials

3

Companies Involved

COVID-19 Infection is an early-stage landscape with 5 programs across 3 companies. The most active players are Pfizer, Gilead, TSANG Hector Wing-Hong. 4 programs are in Phase 3.

Pipeline Metrics

Competitive Density

32/100

Pipeline Velocity

11/100

Mech. Concentration

100/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Programs by Phase

Modality Breakdown

2programs
Small molecule150%
Vaccine150%

Modality classified for 67% of 6 pipeline programs.

Trial Status

6

clinical trials

Recruiting3 · 50%
Active, not recruiting2 · 33%
Completed1 · 17%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)